177-Lu-DOTATATE in 382 patients with somatostatin receptor–positive advanced tumors: Real-world data from the SEPTRALU registry

#3566

Introduction: NETTER-I and ERASMUS clinical trials have led to Lutetium177-DOTATATE (Lu177) approval in Spain.

Aim(s): The aim was to describe the characteristics of patients and tumors treated with Lu177 and to evaluate efficacy and safety in real-word.

Materials and methods: The data come from the SEPTRALU (Spanish sEries of Patients TReAted with 177LU) multicenter (23 hospitals) study. Patients with SSTR–positive advanced tumors of different location and histology were included. Survival was evaluated using the Kaplan-Meier method. Toxicity was recorded according to CTCAEv3.0 criteria.

Conference:

Presenting Author: Mitjavila M

Authors: Mitjavila Casanovas M, Pubul V, Belló P, García-Burillo A, Arbizu J,

Keywords: 177Lu-DOTATATE, SSTR-positive, efficacy, safety,